Pharmafile Logo

New analysis shows emergency hospital admissions for people with Multiple Sclerosis continue to rise

April 26, 2017 | Emergency care, Multiple Sclerosis 

Updated data published by Wilmington Healthcare and the MS Trust highlights need for more preventative care for MS patients

Emergency hospital admissions for people with Multiple Sclerosis (MS) are on the rise and costing the NHS millions; yet many of them could be avoided, according to a new summary of data by healthcare intelligence provider Wilmington Healthcare and the charity, the Multiple Sclerosis (MS) Trust.  

The information, which updates the authors’ previous analysis of English Hospital Episode Statistics (HES) from 2013/14, shows that emergency hospital admissions for people with MS in England increased by 12.7 percent over the two years to 2015/16.
 

According to the latest HES data, there were 26,679 emergency hospital admissions for people with MS in England in 2015/16, compared to 23,665 in 2013/14, and this cost the NHS a total of £46m.  

However, a large proportion of this emergency care was for problems which could have been avoided with proactive, preventative care and earlier diagnosis and intervention in the community.
 

For example, the report found that urinary tract infections accounted for 14 percent of emergency admissions for MS in 2015/16 and they cost £2,639 per patient; while respiratory issues cost the NHS a total of £5.4m.   Overall, admissions for bladder and bowel related issues for people with MS cost £10.4m in 2015/16.
 

The report found that nearly one in five of the 89,030 people living with MS in England were admitted to hospital as an emergency in 2015/16.  The average cost per admission was £1,733 and the average length of stay was 8.2 days.
 

Sue Thomas, CEO of the Commissioning Excellence Directorate for Wilmington Healthcare, said: “Our latest report shows that the problems we highlighted in our original 2013/14 analysis have increased in the past couple of years. A growing number of patients with MS are being admitted to hospital for emergency care; yet many of these admissions could have been avoided with earlier intervention.  

“Preventative care strategies for people with MS must be reviewed in order to tackle problems, such as respiratory and urinary tract infections, at an early stage to try to avert the need for emergency care. This would not only be of huge benefit to patients, it would also reduce pressure on struggling A&E departments.”  

Pam Macfarlane, Chief Executive of the MS Trust, which provides information for people with MS and supports MS specialist services, said: “It is disappointing to see that avoidable emergency hospital admissions for people with MS have continued to rise in 2015/16.
 

“Last November, the MS Trust brought together partners from across the MS sector to publish the MS Forward View consensus. This showed that people with MS need a flexible blend of care, comprising disease modification and also proactive symptom management and neurorehabilitation, delivered by multidisciplinary teams. This is one reason why we are now funding additional MS nurses in areas of the UK where services are the most overstretched. Only with the right specialist and community based support will we reduce the need for emergency hospital care for people with MS.”  


                                                                        Ends

This content was provided by Wilmington Healthcare

Company Details

 Latest Content from  Wilmington Healthcare 

Wilmington Healthcare launches new platform to map the formulary landscape

Healthcare intelligence provider Wilmington Healthcare has launched a new platform that enables pharma companies to develop a clear picture of formulary status across therapy areas and territories in the UK.

Wilmington Healthcare appoints new Head of Digital

Wilmington Healthcare, which provides data, insight and intelligence for pharma and medtech companies, has appointed Pfizer’s former UK Digital Marketing Manager, Mikko Figura, as Head of Digital.In his new role,...

How has the pandemic reshaped the NHS in 2020?

Oli Hudson, of Wilmington Healthcare, explores the major changes that have occurred across the NHS as key aspects of the Long Term Plan are rolled out at speed.

Harness the power of data to map new patient pathways

Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset

How can pharma align its brand strategy with the NHS Reset?

Oli Hudson, of Wilmington Healthcare, explores how pharma should respond to plans to ‘reboot’ the NHS during the covid recovery era

Covid-19 redefines rules of customer engagement

Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs

White paper helps industry navigate new NHS roadmap

New report shows how pharma can support the NHS in the Covid-19 recovery era

Covid-19 drives change in long-term conditions management

Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore how patients are being empowered to manage their conditions at home

Covid-19: how is it impacting on the NHS Long-term Plan?

Oli Hudson and Paul Midgley, of Wilmington Healthcare, explain how coronavirus has expedited some parts of the plan but put others in jeopardy

Covid-19: what could it mean for the diabetic population?

Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it